目的 探討丹參酮Ⅱ_A磺酸鈉聯(lián)合阿羅洛爾治療不穩(wěn)定型心絞痛的臨床療效。方法 選取2022年3月—2023年3月在武漢市中醫(yī)醫(yī)院進行診治的不穩(wěn)定型心絞痛患者185例，根據(jù)治療方案差異將患者分成對照組（93例）和治療組（92例）。對照組患者口服鹽酸阿羅洛爾片，1片/次，2次/d；治療組在對照組基礎上靜脈滴注丹參酮Ⅱ_A磺酸鈉注射液，40 mg藥物加入100 mL生理鹽水，1次/d；兩組患者均進行2周的治療。觀察兩組患者臨床療效，比較治療前后兩組患者心功能指標左室收縮末徑（LVESD）、左室射血分數(shù)（LVEF）和6 min步行距離，血清可溶性ST2（sST2）、心肌肌鈣蛋白I（cTnI）、單核細胞趨化蛋白-1（MCP-1）、轉化生長因子-β結合蛋白2（LTBP-2）和血管擴張刺激磷蛋白（VASP）水平，及心絞痛視覺模擬量表（VAS）評分和生活質量綜合評定問卷（GQOLI-74）評分。結果 治療后，對照組和治療組臨床總有效率分別為82.80%和97.83%，兩組比較差異具有統(tǒng)計學意義（P＜0.05）。治療后，兩組患者心功能指標LVEF和6 min步行距離明顯增加，而LVESD則明顯下降（P＜0.05），且治療組心功能相關指標改善更為明顯（P＜0.05）。治療后，兩組患者血清sST2、cTnI、MCP-1、LTBP-2水平均明顯降低，而VASP水平則明顯升高（P＜0.05），且治療組各指標改善更為明顯（P＜0.05）。治療后，兩組患者心絞痛VAS評分明顯降低，而GQOLI-74評分則明顯升高（P＜0.05），且治療組改善更明顯（P＜0.05）。結論 丹參酮Ⅱ_A磺酸鈉聯(lián)合阿羅洛爾治療不穩(wěn)定型心絞痛療效顯著，不僅能夠顯著改善患者心功能和促進血清學指標的恢復，同時還能夠提升患者生活質量。

Objective To explore the effectiveness of sulfotanshinone sodium combined with arotinolol in treatment of unstable angina pectoris. Methods Patients (185 cases) with unstable angina pectoris in Wuhan Hospital of Traditional Chinese Medicine from March 2022 to March 2023 were divided into control (93 cases) and treatment (92 cases) group based on different treatments. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Sulfotanshinone Sodium Injection on the basis of the control group, 40 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluations were evaluated, the cardiac function related indicators LVEF, LVESD and 6 min walking distance, the levels of serum sST2, cTnI, MCP-1, LTBP-2 and VASP, and the scores of VAS and GQOLI-74 in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 82.80% and 97.83% respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the indexes of LVEF and 6 min walking distance were significantly increased, while LVESD was significantly decreased in two groups (P < 0.05), and the related indexes ofcardiac function were improved more significantly in the treatment group (P < 0.05). After treatment, the serum levels of sST2, cTnI, MCP-1 and LTBP-2 were significantly decreased, while the level of VASP was significantly increased in two groups (P < 0.05), and the improvement of each index in the treatment group was more obvious (P < 0.05). After treatment, the VAS score of angina pectoris was significantly decreased, while the GQOLI-74 score was significantly increased in two groups (P < 0.05), and the improvement was more obvious in the treatment group (P < 0.05). Conclusion Sulfotanshinone Sodium Injection combined with aroprolol has significant therapeutic effects on unstable angina pectoris, which can not only significantly improve the cardiac function and promote the recovery of serological indexes, but also improve the quality of life of patients.

R972

湖北省自然科學基金資助項目（2022CFC002）